<DOC>
	<DOCNO>NCT02248701</DOCNO>
	<brief_summary>The purpose study determine whether testosterone plus finasteride treatment improve musculoskeletal health , neuromuscular function , body composition , metabolic health hypogonadal men experience ambulatory dysfunction subsequent incomplete spinal cord injury . The investigator hypothesize treatment improve bone mineral density , enhance muscle size muscle function , improve body composition , without cause prostate enlargement .</brief_summary>
	<brief_title>Testosterone Plus Finasteride Treatment After Spinal Cord Injury</brief_title>
	<detailed_description>Men spinal cord injury ( SCI ) experience high prevalence hypogonadism influence neural , muscular , skeletal , body composition deficit occur injury . It remain unknown whether testosterone administration improve bone mineral density , muscle mass muscle function , body composition / metabolic health hypogonadal men experience ambulatory dysfunction subsequent incomplete spinal cord injury . In addition , unknown whether testosterone 5-alpha reduce metabolite dihydrotestosterone ( endogenous metabolite testosterone ) mediate effect tissue . For study hypogonadal men motor incomplete spinal cord injury present ambulatory dysfunction randomize receive testosterone plus 5-alpha reductase inhibitor finasteride placebo treatment 12 month . Testosterone placebo injection administer weekly ; finasteride placebo administer daily . Participants assess study entry 1-6 month interval thereafter . Assessments include measurement dual energy x-ray absorptiometry ( DEXA ) scan , MRI scan , muscle performance test . Participants also several safety test , include electrocardiogram ( EKG ) cardiac electrophysiology , prostate digital rectal exam prostate ultrasound size prostate health , blood test assess hematocrit , liver enzymes ( AST ALT ) , prostate specific antigen ( PSA ) , cholesterol , health marker .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Genital Diseases , Male</mesh_term>
	<mesh_term>Trauma , Nervous System</mesh_term>
	<mesh_term>Gonadal Disorders</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Antineoplastic Agents , Hormonal</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<criteria>Male &gt; 18 year age Traumatic , vascular , orthopedic spinal cord injury C4T7 &gt; 12 month prior enrollment Motor incomplete spinal cord ( AIS C/D ) Ambulatory dysfunction Medically stable condition asymptomatic bladder infection , decubiti , cardiopulmonary disease , significant medical condition Serum total testosterone ( &lt; 325 ng/dL ) bioavailable testosterone ( &lt; 70 ng/dL ) Currently participate another research protocol may influence study outcome Life expectancy &lt; 1 year History current congenital spinal cord injury degenerative spinal disorder Diagnosis multiple sclerosis , amyotrophic lateral sclerosis , neurologic impairment/injury History thromboembolic disease Poorly compensate uncontrolled cardiovascular disease Acute myocardial infarction within last 6 month Any cardiac revascularization procedure within last 6 month , include angioplasty coronary bypass graft Any cardiovascularrelated hospitalization within last 6 month Any major cardiovascular event within last 6 month Any angina control current medical regimen ( Canadian class II , III , IV ) New York Heart Association ( NYHA ) class III IV congestive heart failure Systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 90 mm Hg Poorly control arrhythmia Severe valvular disease History stroke LDL cholesterol &gt; 160 mg/dl know history myocardial infarction , ischemic heart disease , stroke Baseline EKG finding ( e.g . leave bundle branch block ) mark EKG abnormality would preclude serial screen occult ischemic event History current prostate , breast , organ cancer Serum prostatespecific antigen ( PSA ) &gt; 3.0 ng/ml Hematocrit &gt; 47 % Liver enzymes ( AST / ALT ) normal upper limit Creatinine &gt; 1.4 mg/dL Serum calcium &gt; 10.5 mg/dL Gynecomastia Mental state precludes understand protocol Diagnosed , untreated sleep apnea Spinal nutrition screen tool score &gt; 15 Presence nonMRI compatible implant severe claustrophobia precludes MRI test Current anticoagulant therapy Use follow pharmacologic agent previous 3 month ( testosterone , leuprolide , androgenic hormone , growth hormone , oral androgen precursor , 5alpha reductase aromatase inhibitor ) Use antiresorptive bone anabolic drug therapy previous 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Testosterone enanthate</keyword>
	<keyword>Testosterone undecanoate</keyword>
	<keyword>Testosterone 17 beta-cypionate</keyword>
	<keyword>Methyltestosterone</keyword>
	<keyword>Androgens</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormone Substitutes , Hormone Antagonists</keyword>
	<keyword>Physiologic Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antineoplastic Agents , Hormonal</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Anabolic Agents</keyword>
	<keyword>Testosterone Replacement Therapy</keyword>
	<keyword>Dual Energy X ray Absorptiometry</keyword>
	<keyword>Lean Tissue Mass</keyword>
	<keyword>Body Composition</keyword>
	<keyword>Lipid Glucose profile</keyword>
	<keyword>Muscle Strength</keyword>
	<keyword>5-alpha Reductase</keyword>
	<keyword>Muscle Mass</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Adipose Tissue</keyword>
	<keyword>Body Fat</keyword>
	<keyword>Density , Bone</keyword>
	<keyword>Bone Formation</keyword>
	<keyword>Bone Resorption</keyword>
	<keyword>Bone Density Conservation Agents</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Muscle , Skeletal</keyword>
	<keyword>Bone Bones</keyword>
	<keyword>Gait</keyword>
	<keyword>Walking</keyword>
	<keyword>Locomotion</keyword>
	<keyword>Motor Activity</keyword>
</DOC>